Serum galectin-3 levels are decreased in schizophrenia
AUTOR(ES)
Kiliç, Faruk; Işik, Ümit; Demirdaş, Arif; Usta, Ayşe
FONTE
Braz. J. Psychiatry
DATA DE PUBLICAÇÃO
2020-08
RESUMO
Objective: To determine whether changes in serum galectin-3 (gal-3) concentrations in schizophrenia patients have etiopathogenetic importance. Since very little research has assessed the connection between galectins and schizophrenia, we wanted to examine alterations in the inflammatory marker gal-3 in schizophrenia and investigate possible correlations between clinical symptomatology and serum concentrations. Methods: Forty-eight schizophrenia patients and 44 healthy controls were included in this study. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for the Assessment of Negative Symptoms (SANS) were administered to determine symptom severity. Venous blood samples were collected, and serum gal-3 levels were measured. Results: Mean serum gal-3 levels were significantly lower in schizophrenia patients, and there were no significant differences in age or sex with the control group. There was also a significant positive correlation between serum gal-3 concentrations and negative schizophrenia symptoms according to the SANS. Conclusion: The results indicate that gal-3 is decreased in schizophrenia patients, which could contribute to inflammation in the pathogenesis of schizophrenia.
Documentos Relacionados
- Critical role of galectin-3 in phagocytosis by macrophages
- Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein
- Expression of galectin-3 modulates T-cell growth and apoptosis.
- Galectin-3 Overexpression in Invasive Laryngeal Carcinoma, Assessed by Computer-assisted Analysis
- Identification of galectin-3 as a factor in pre-mRNA splicing.